Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid Tumors

NCT06573294 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT06573294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06573294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1
Overall status
Terminated
Start date
August 28, 2024
Completion date
April 7, 2026
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors, metastatic malignant solid tumors